Castle Biosciences (CSTL)
(Delayed Data from NSDQ)
$19.31 USD
+0.11 (0.57%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $19.28 -0.03 (-0.16%) 6:34 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CSTL 19.31 +0.11(0.57%)
Will CSTL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CSTL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CSTL
Castle Biosciences, Inc. (CSTL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
CSTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Insights Into Castle Biosciences, Inc. (CSTL) Q4: Wall Street Projections for Key Metrics
Strength Seen in Alector (ALEC): Can Its 6.0% Jump Turn into More Strength?
How Much Upside is Left in Castle Biosciences, Inc. (CSTL)? Wall Street Analysts Think 67.01%
Other News for CSTL
CSTL Makes Notable Cross Below Critical Moving Average
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
Commit To Buy Castle Biosciences At $15, Earn 11.8% Annualized Using Options